Laurus Labs Q2 profit more than doubles; analyst views diverge sharply

Laurus Labs reported substantially improved financial performance in the quarter ended September, with net profit more than doubling from the prior-year period. The company's revenue increased 33.5% while earnings before interest, tax, depreciation and amortization surged 86.3%, signaling robust operational momentum across its pharmaceutical business.

The strong results triggered a reassessment from Jefferies, which raised its price target on the stock to Rs 2,100, reflecting confidence in the company's growth trajectory. The upgrade comes as Laurus Labs continues to expand its manufacturing capabilities and market presence in key therapeutic segments.

However, optimism is not universal among the analyst community. Kotak Institutional Equities and Goldman Sachs both maintained Sell ratings on the stock, suggesting they see downside risks or valuation concerns that outweigh the near-term operational improvements. The divergence in views reflects ongoing debate about the sustainability of Laurus Labs' growth and competitive positioning in the pharmaceutical sector.

The mixed analyst sentiment underscores the complexity facing investors in evaluating mid-sized pharmaceutical companies, where strong quarterly performance must be weighed against longer-term structural challenges and valuation multiples. Laurus Labs' next catalysts will likely include updates on pipeline progress and guidance on sustained margin expansion.